Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial-Reference-Cited by-同舟云学术

Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial

Published:2022-04-01 Issue:6 Volume:13 Page:e00492
ISSN:2155-384X
Container-title:Clinical and Translational Gastroenterology
language:en
Short-container-title:Clinical and Translational Gastroenterology

Author:

Saviano Antonio,Habersetzer François,Lupberger Joachim,Simo-Noumbissie Pauline,Schuster Catherine,Doffoël Michel,Schmidt-Mutter Catherine,Baumert Thomas F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology

Reference37 articles.

1. Burden of liver diseases in the world;Asrani;J Hepatol,2019

2. Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies;Zoulim;Gut,2015

3. EASL recommendations on treatment of hepatitis C: Final update of the series;J Hepatol,2020

4. Curing chronic hepatitis C—the arc of a medical triumph;Chung;N Engl J Med,2014

5. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges;Baumert;Gastroenterology,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling pathways in liver cancer: pathogenesis and targeted therapy;Molecular Biomedicine;2024-05-31

2. A Novel RNA Methylation-Related Prognostic Signature and its Tumor Microenvironment Characterization in Hepatocellular Carcinoma;Technology in Cancer Research & Treatment;2024-01

3. The matrix metalloproteinase ADAM10 supports hepatitis C virus entry and cell-to-cell spread via its sheddase activity;PLOS Pathogens;2023-11-15

4. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives;Current Issues in Molecular Biology;2023-10-11

5. Genetic and pharmacological perturbation of hepatitis-C virus entry;Current Opinion in Virology;2023-10